Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RET rearrangement
i
Other names:
RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5979
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
cabozantinib tablet
Sensitive: A2 - Guideline
cabozantinib tablet
Sensitive
:
A2
cabozantinib tablet
Sensitive: A2 - Guideline
cabozantinib tablet
Sensitive
:
A2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
sunitinib
Sensitive: C2 – Inclusion Criteria
sunitinib
Sensitive
:
C2
sunitinib
Sensitive: C2 – Inclusion Criteria
sunitinib
Sensitive
:
C2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
vandetanib
Sensitive: C3 – Early Trials
vandetanib
Sensitive
:
C3
vandetanib
Sensitive: C3 – Early Trials
vandetanib
Sensitive
:
C3
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
selpercatinib + pralsetinib
Sensitive: C3 – Early Trials
selpercatinib + pralsetinib
Sensitive
:
C3
selpercatinib + pralsetinib
Sensitive: C3 – Early Trials
selpercatinib + pralsetinib
Sensitive
:
C3
RET rearrangement
Lung Adenocarcinoma
RET rearrangement
Lung Adenocarcinoma
cabozantinib tablet
Sensitive: C3 – Early Trials
cabozantinib tablet
Sensitive
:
C3
cabozantinib tablet
Sensitive: C3 – Early Trials
cabozantinib tablet
Sensitive
:
C3
RET rearrangement
Thyroid Gland Carcinoma
RET rearrangement
Thyroid Gland Carcinoma
selumetinib
Sensitive: D – Preclinical
selumetinib
Sensitive
:
D
selumetinib
Sensitive: D – Preclinical
selumetinib
Sensitive
:
D
RET rearrangement
Thyroid Gland Papillary Carcinoma
RET rearrangement
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
RET rearrangement
Thyroid Gland Carcinoma
RET rearrangement
Thyroid Gland Carcinoma
AZD1480
Sensitive: D – Preclinical
AZD1480
Sensitive
:
D
AZD1480
Sensitive: D – Preclinical
AZD1480
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login